853 Evofosfomide potentiates the efficacy of a novel anti-PD-L1/PD-L2 monoclonal antibody against immune excluded tumors

• Michael Curran,
• James Barlow,
• Ahmad Salameh,
• Paul Blezinger,
• Christine Gagliardi,
• Matt Hemberger,
• Federica Pericle

Affiliations

Michael Curran

Aff7 0000 0001 2291 4776grid.240145.6Department of Investigational Cancer TherapeuticsThe University of Texas MD Anderson Cancer Center 1515 Holcombe Blvd., Unit 0455 77030 Houston TX USA

James Barlow

1ImmunoGenesis, Inc., Houston, TX, USA

Ahmad Salameh

1ImmunoGenesis, Inc., Houston, TX, USA

Paul Blezinger

1ImmunoGenesis, Inc., Houston, TX, USA

Christine Gagliardi

1ImmunoGenesis, Inc., Houston, TX, USA

Matt Hemberger

1ImmunoGenesis, Inc., Houston, TX, USA

Federica Pericle

1ImmunoGenesis, Inc., Houston, TX, USA